Skip to main content
Premium Trial:

Request an Annual Quote

John Berriman

Premium
Solexa co-founder John Berriman has become chairman of Belgian biomarker company Pronota, the company said last week. Berriman is also chairman of Algeta and a director at MicroMet, Ablynx, and Oxxon Therapeutics.
 
Previously, he was a director at Abingworth Management, after working at Celltech Group. In addition, he was a director at Solexa, Epigenomics, Alnylam, and XCounter, and chairman of Chroma Therapeutics.
 
Berriman holds a chemical engineering degree from the University of Cambridge and an MBA from the London Business School.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.